Prescription medicine
Benazepril and hydrochlorothiazide Brand names: Lotensin; first approved as Lotensin Hct
Benazepril and hydrochlorothiazide (Lotensin) is a prescription medicine with an FDA approval on record since 1992. FDA's NDC Directory lists it from 3 generic labelers, and pharmacies paid $0.222 per benazepril-hydrochlorothiazide 20-12.5 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
- Boxed warning
Check it at the source: the benazepril and hydrochlorothiazide FDA label on DailyMed (effective February 24, 2026, Validus Pharmaceuticals LLC); the NDA 20033 record on Drugs@FDA; every benazepril and hydrochlorothiazide label on DailyMed.
Highlights of the record
FDA label of February 24, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
FETAL TOXICITY.
When pregnancy is detected, discontinue Lotensin HCT as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (see WARNINGS: Fetal Toxicity ).
Used for
From the label: indications and usageLotensin HCT USP is indicated for the treatment of hypertension.
Forms and strengths
- 5 mg / 6.25 mg
- 10 mg / 12.5 mg
- 20 mg / 12.5 mg
- 20 mg / 25 mg
Tablet; film-coated tablet.
On the market
- Earliest approval on file
- May 19, 1992 Lotensin Hct, Validus Pharms; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 7 first February 11, 2004; 2 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 7 of which 3 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.222 per tablet Benazepril-hydrochlorothiazide 20-12.5 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 447 through July 30, 2026
What is benazepril and hydrochlorothiazide used for?
From the label: indications and usageLotensin HCT USP is indicated for the treatment of hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension ( see DOSAGE AND ADMINISTRATION ).
Conditions named in the indications of benazepril and hydrochlorothiazide's FDA labels, with every medicine labeled for each:
From other benazepril and hydrochlorothiazide labelsHigh blood pressure: INDICATIONS AND USAGE Lotensin HCT USP is indicated for the treatment of hypertension.
FDA pharmacologic class: Angiotensin Converting Enzyme Inhibitor and Thiazide Diuretic.
Source: FDA drug label (Lotensin HCT), Validus Pharmaceuticals LLC, effective February 24, 2026 (SPL set 94c4536f-e28e-48b1-8336-b3939917e99d), via openFDA; the full label on DailyMed
Is there a generic for benazepril and hydrochlorothiazide (Lotensin)?
The FDA approved the first generic benazepril and hydrochlorothiazide on February 11, 2004. 7 generic applications are approved; 2 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists benazepril and hydrochlorothiazide from 3 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1992 earliest approval on file
- 2004 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for benazepril and hydrochlorothiazide (Lotensin)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.222 per Benazepril-hydrochlorothiazide 20-12.5 mg tablet, down 6% from $0.235 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Benazepril-hydrochlorothiazide 20-12.5 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Benazepril-hydrochlorothiazide 10-12.5 mg tablet | Generic | $0.227 per tablet | $6.80 | +0.8% |
| Benazepril-hydrochlorothiazide 20-12.5 mg tablet | Generic | $0.222 per tablet | $6.65 | -6% |
| Benazepril-hydrochlorothiazide 20-25 mg tablet | Generic | $0.253 per tablet | $7.58 | +5% |
| Benazepril-hydrochlorothiazide 5-6.25 mg tablet | Generic | $0.509 per tablet | $15.28 | -17% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the benazepril and hydrochlorothiazide label say about other medicines?
The benazepril and hydrochlorothiazide label names 18 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Aliskiren | contraindications | Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin HCT in patients with diabetes. |
| Atropine | drug interactions | Drugs that alter gastrointestinal motility: The bioavailability of thiazide-type diuretics may be increased by anticholinergic agents (e.g., atropine, biperiden), apparently due to a decrease in gastrointestinal motility and the stomach emptying rate. |
| Captopril | warnings | Neutropenia/Agranulocytosis Another angiotensin-converting enzyme inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated patients (incidence probably less than once per 10,000 exposures) but more frequently (incidence possibly as great as once per 1000 … |
| Cholestyramine | drug interactions | Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively. |
| Cimetidine | drug interactions | Benazepril Benazepril has been used concomitantly with beta-adrenergic-blocking agents, calcium-blocking agents, cimetidine, diuretics, digoxin, hydralazine, and naproxen without evidence of clinically important adverse interactions. |
| Colestipol | drug interactions | Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively. |
| Cyclophosphamide | drug interactions | Antineoplastic agents (e.g., cyclophosphamide, methotrexate): Concomitant use of thiazide diuretics may reduce renal excretion of cytotoxic agents and enhance their myelosuppressive effects. |
| Digoxin | drug interactions | Digitalis glycosides: Thiazide-induced hypokalemia or hypomagnesemia may predispose the patients to digoxin toxicity Skeletal muscle relaxants: |
| Epinephrine | warnings | When involvement of the tongue, glottis, or larynx appears likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine injection 1:1000 (0.3 - 0.5 mL) should be promptly administered ( see PRECAUTIONS and ADVERSE REACTIONS ). |
| Everolimus | drug interactions | Monitor potassium periodically. mTOR (mammalian target of rapamycin) inhibitors: Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema ( see WARNINGS ). |
| Hydralazine | drug interactions | Benazepril Benazepril has been used concomitantly with beta-adrenergic-blocking agents, calcium-blocking agents, cimetidine, diuretics, digoxin, hydralazine, and naproxen without evidence of clinically important adverse interactions. |
| Lithium | drug interactions | Renal clearance of lithium is reduced by thiazides and increase the risk of lithium toxicity. |
| Methotrexate | drug interactions | Antineoplastic agents (e.g., cyclophosphamide, methotrexate): Concomitant use of thiazide diuretics may reduce renal excretion of cytotoxic agents and enhance their myelosuppressive effects. |
| Naproxen | drug interactions | Benazepril Benazepril has been used concomitantly with beta-adrenergic-blocking agents, calcium-blocking agents, cimetidine, diuretics, digoxin, hydralazine, and naproxen without evidence of clinically important adverse interactions. |
Every other medicine the benazepril and hydrochlorothiazide label names
| Medicine named | Section | What the label says |
|---|---|---|
| Sacubitril and valsartan | contraindications | Do not administer Lotensin HCT within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see WARNINGS and PRECAUTIONS ). |
| Sirolimus | drug interactions | … receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema ( see WARNINGS ). |
| Temsirolimus | drug interactions | … receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema ( see WARNINGS ). |
| Warfarin | drug interactions | Interaction studies with warfarin and acenocoumarol have failed to identify any clinically important effects of benazepril on the serum concentrations or clinical effects of these anticoagulants. |
Check benazepril and hydrochlorothiazide against other medicines
Source: FDA drug label (Lotensin HCT), Validus Pharmaceuticals LLC, effective February 24, 2026 (SPL set 94c4536f-e28e-48b1-8336-b3939917e99d), via openFDA; the full label on DailyMed
What do FAERS reports show for benazepril and hydrochlorothiazide?
The FDA Adverse Event Reporting System holds 447 reports that list benazepril and hydrochlorothiazide among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 27 are coded as a death and 146 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as benazepril and hydrochlorothiazide?
55 other medicines are given the same way (oral) and in the same FDA class as benazepril and hydrochlorothiazide or labeled mainly for the same use (high blood pressure), the same class first. High blood pressure lists all 88 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Lisinopril | High blood pressure | 36 labelers | $0.0254 per tablet 20 mg tablet | No current entry |
| Enalapril | High blood pressure | 29 labelers | $0.0664 per tablet 10 mg tablet | No current entry |
| Ramipril | High blood pressure | 17 labelers | $0.0707 per capsule 10 mg capsule | No current entry |
| Captopril | High blood pressure | 13 labelers | $0.228 per tablet 12.5 mg tablet | No current entry |
| Quinapril | High blood pressure | 9 labelers | n/a | In shortage |
| Fosinopril | High blood pressure | 7 labelers | $0.154 per tablet 10 mg tablet | No current entry |
| Trandolapril | High blood pressure | 5 labelers | $0.157 per tablet 1 mg tablet | No current entry |
| Trandolapril and verapamil | High blood pressure | 1 labeler | n/a | No current entry |
Every medicine labeled for the same conditions as benazepril and hydrochlorothiazide
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to benazepril and hydrochlorothiazide
- 55 medicines for the same use
- Other ACE inhibitors
- the pharmacologic class, with prices and generics
- Benazepril and hydrochlorothiazide side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other